Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | MicrobiomeTrials← Back to trialsNCT06855277
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
RecruitingPHASE3INTERVENTIONAL
Trial Details
Start: 2025-07-01Est. Completion: 2028-09-29
Enrollment target: 940 participants Locations- Urology Centers Of Alabama Pc, Homewood, Alabama, United States
- Stanford University Medical Center, Palo Alto, California, United States
- Sansum Clinic, Santa Barbara, California, United States
- Rocky Mountain Cancer Centers, Denver, Colorado, United States
- Florida Cancer Specialists, Fort Myers, Florida, United States
- Baptist Health South, Miami, Florida, United States
- AdventHealth, Orlando, Florida, United States
- University Cancer and Blood Center LLC, Athens, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Univ Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States
- University of Kansas Hospital, Kansas City, Kansas, United States
- East Jefferson Hospital, Metairie, Louisiana, United States
- Beth Israel Deaconess Med Center, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Wash U School of Medicine, St Louis, Missouri, United States
Other microbiome trials you might be interested in
Prostate Cancer
In this exploratory, single-arm, nonrandomized trial, the impact of the preoperative utilization of the glucagon-like pe…
Gilbert, United StatesEst. completion May 2028
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid TumorUrinary Bladder NeoplasmTriple Negative Breast CancerNon-small Cell Lung CancerEsophageal CancerPancreatic Cancer
Nebraska Cancer Specialists, Omaha, Nebraska, United StatesAstera Cancer Center, East Brunswick, New Jersey, United StatesNew Jersey Urology LLC, Voorhees Township, New Jersey, United StatesBassett Medical Center, Cooperstown, New York, United StatesWeill Cornell Medicine NY-Presb, New York, New York, United StatesUniversity of Rochester Medical Ctr, Rochester, New York, United StatesAssociated Med Professionals of NY, Syracuse, New York, United StatesMontefiore Medical Center, The Bronx, New York, United StatesCentral Ohio Urology Group, Gahanna, Ohio, United StatesMUSC Hollings Cancer Center, Charleston, South Carolina, United StatesCarolina Urologic Research Center, Myrtle Beach, South Carolina, United StatesTennessee Oncology PLLC, Chattanooga, Tennessee, United StatesUrology San Antonio, San Antonio, Texas, United StatesWoodlands Cancer Institute American Oncology Partners, The Woodlands, Texas, United StatesSwedish Medical Center, Seattle, Washington, United StatesNorthwest Medical Specialties, Tacoma, Washington, United StatesMedical College of Wisconsin, Milwaukee, Wisconsin, United StatesNovartis Investigative Site, Darlinghurst, New South Wales, AustraliaNovartis Investigative Site, Adelaide, South Australia, AustraliaNovartis Investigative Site, Malvern, Victoria, AustraliaNovartis Investigative Site, Murdoch, Western Australia, AustraliaNovartis Investigative Site, Adelaide, AustraliaNovartis Investigative Site, São Paulo, São Paulo, BrazilNovartis Investigative Site, São Paulo, São Paulo, BrazilNovartis Investigative Site, Fuzhou, Fujian, ChinaNovartis Investigative Site, Guangzhou, Guangdong, ChinaNovartis Investigative Site, Guangzhou, Guangdong, ChinaNovartis Investigative Site, Wuhan, Hubei, ChinaNovartis Investigative Site, Wuhan, Hubei, ChinaNovartis Investigative Site, Nanjing, Jiangsu, ChinaNovartis Investigative Site, Nanjing, Jiangsu, ChinaNovartis Investigative Site, Shenyang, Liaoning, ChinaNovartis Investigative Site, Chengdu, Sichuan, ChinaNovartis Investigative Site, Hangzhou, Zhejiang, ChinaNovartis Investigative Site, Beijing, ChinaNovartis Investigative Site, Beijing, ChinaNovartis Investigative Site, Guangzhou, ChinaNovartis Investigative Site, Shanghai, ChinaNovartis Investigative Site, Shanghai, ChinaNovartis Investigative Site, Shanghai, ChinaNovartis Investigative Site, Tianjin, ChinaNovartis Investigative Site, Tianjin, ChinaNovartis Investigative Site, Hong Kong, Hong KongNovartis Investigative Site, Gurgaon, Haryana, IndiaNovartis Investigative Site, Bengaluru, Karnataka, IndiaNovartis Investigative Site, Mumbai, Maharashtra, IndiaNovartis Investigative Site, Nagoya, Aichi-ken, JapanNovartis Investigative Site, Sapporo, Hokkaido, JapanNovartis Investigative Site, Kobe, Hyōgo, JapanNovartis Investigative Site, Kobe, Hyōgo, JapanNovartis Investigative Site, Yokohama, Kanagawa, JapanNovartis Investigative Site, Chuo Ku, Tokyo, JapanNovartis Investigative Site, Chiba, JapanNovartis Investigative Site, Fukuoka, JapanNovartis Investigative Site, Fukuoka, JapanNovartis Investigative Site, Fukuoka, JapanNovartis Investigative Site, Fukushima, JapanNovartis Investigative Site, Hiroshima, JapanNovartis Investigative Site, Kyoto, JapanNovartis Investigative Site, Singapore, SingaporeNovartis Investigative Site, Singapore, SingaporeNovartis Investigative Site, Singapore, SingaporeNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Seoul, South KoreaNovartis Investigative Site, Kaohsiung City, TaiwanNovartis Investigative Site, Taipei, TaiwanNovartis Investigative Site, Taoyuan, TaiwanNovartis Investigative Site, Sutton, Surrey, United KingdomOvarian Cancer
Cervical Cancer
Head and Neck Squamous Cell Carcinoma
Prostate Cancer
Renal Pelvis Cancer
Bladder Cancer
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in particip…
Duarte, United StatesEst. completion May 2027
Advanced/Metastatic Solid Tumors
This is a multicenter, open-label, multiple-dose, FIH Phase 1a/1b study. Phase 1a adopts an accelerated titration design…
Los Angeles, United StatesEst. completion Jun 2028